Antiretroviral Drug Concentrations in Breastmilk, Maternal HIV Viral Load, and HIV Transmission to the Infant: Results From the BAN Study

Nicole L Davis, Amanda Corbett, Josh Kaullen, Julie A E Nelson, Charles S Chasela, Dorothy Sichali, Michael G Hudgens, William C Miller, Denise J Jamieson, Athena P Kourtis, Nicole L Davis, Amanda Corbett, Josh Kaullen, Julie A E Nelson, Charles S Chasela, Dorothy Sichali, Michael G Hudgens, William C Miller, Denise J Jamieson, Athena P Kourtis

Abstract

Background: Concentration of antiretroviral (ARV) drug found in plasma, and amounts of drug excreted into breastmilk, may affect HIV viral load and potentially perinatal HIV transmission.

Methods: In this cohort study with 2-phase sampling, we included mothers randomized to postpartum maternal ARVs or daily infant nevirapine during 28 weeks of breastfeeding in the Breastfeeding, Antiretrovirals, and Nutrition study. Among these, we included all mothers who transmitted HIV to their infants between 2 and 28 weeks and 15% of mothers who did not (n = 27 and 227, respectively). Spearman correlation coefficients (r) were used to assess the correlation between maternal plasma and breastmilk ARV concentration. Associations between the median effective drug concentration (EC50) and detectable maternal viral load (plasma: >40 copies per milliliter, breastmilk: >56 copies per milliliter) were assessed using mixed-effects models. Cox models were used to estimate the association between maternal or infant plasma drug concentration and breastmilk HIV transmission from 2 to 28 weeks.

Results: All ARV compounds exhibited substantial correlations between maternal plasma and breastmilk concentrations (r: 0.85-0.98, P-value <0.0001). Having plasma drug concentration above the EC50 was associated with lower odds of having detectable HIV RNA [maternal plasma odds ratio (OR) 0.64, 95% confidence interval (CI): 0.45 to 0.91; breastmilk OR 0.22, 95% CI: 0.14 to 0.35] and a reduced rate of breastmilk HIV transmission (hazard ratio 0.40, 95% CI: 0.18 to 0.93). Having breastmilk drug concentration above the EC50 was also associated with lower odds of having detectable maternal HIV RNA (plasma OR 0.62, 95% CI: 0.45 to 0.85; breastmilk OR 0.42, 95% CI: 0.29 to 0.59).

Conclusions: Ensuring adequate drug concentration is important for viral suppression and preventing breastmilk HIV transmission.

Conflict of interest statement

Conflict of Interest: W.C.M. reports grants from the National Institutes of Health (NIH) during the conduct of the study. J.A.E.N. reports grants from NIH and CDC during the conduct of the study; grants from Merck, GSK, and Janssen outside the submitted work. M.G.H. reports grants from CDC, NIH, and Gates Foundation during the conduct of the study. The remaining authors have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Correlation (r2) between maternal plasma and breastmilk antiretroviral drug concentrations among 122 Malawian postpartum women, the Breastfeeding, Antiretrovirals, and Nutrition study.

References

    1. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. The New England journal of medicine 1999; 341:394–402.
    1. Corbett AH. Antiretroviral Pharmacology in Breast Milk In: Kourtis PA, Bulterys M, eds. Human Immunodeficiency Virus type 1 (HIV-1) and Breastfeeding: Science, Research Advances, and Policy. New York, NY: Springer New York, 2012:109–18.
    1. Salazar-Gonzalez JF, Salazar MG, Learn GH, et al. Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing. Journal of virology 2011; 85:2751–63.
    1. Fiscus SA, Aldrovandi GM. Virologic determinants of breast milk transmission of HIV-1. Advances in Experimental Medicine and Biology 2012; 743:69–80.
    1. Breslow NE, Lumley T, Ballantyne CM, Chambless LE, Kulich M. Using the whole cohort in the analysis of case-cohort data. American Journal of Epidemiology 2009; 169:1398–405.
    1. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. The New England journal of medicine 2010; 362:2271–81.
    1. Jamieson DJ, Chasela CS, Hudgens MG, et al. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial. Lancet 2012; 379:2449–58.
    1. van der Horst C, Chasela C, Ahmed Y, et al. Modifications of a large HIV prevention clinical trial to fit changing realities: a case study of the Breastfeeding, Antiretroviral, and Nutrition (BAN) protocol in Lilongwe, Malawi. Contemp Clin Trials 2009; 30:24–33.
    1. Rezk NL, White N, Bridges AS, et al. Studies on antiretroviral drug concentrations in breast milk: Validation of a liquid chromatography–tandem mass spectrometric method for the determination of 7 anti-human immunodeficiency virus medications. Therapeutic drug monitoring 2008; 30:611.
    1. Kwaliteitsbewaking Klinische Geneesmiddelanalyse en Toxicologie. In Association for Quality Assessment in TDM and Clinical Toxicology; A section of the Dutch Foundation for Quality Assessment in Medical Laboratories: available at .
    1. National Institute of Allergy and Infectious Diseases. Clinical Pharmacology Quality Assurance Antiretroviral Proficiency Testing Program. In: AIDS Do, ed: Available at .
    1. Viramune® (nevirapine) [package insert] Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2017.
    1. Kaletra® (lopinavir and ritonavir) [package insert]. North Chicago, IL: AbbVie Inc.; 2016.
    1. Zhang KE, Wu E, Patick AK, et al. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrobial agents and chemotherapy 2001; 45:1086–93.
    1. Breslow NE, Lumley T, Ballantyne CM, Chambless LE, Kulich M. Improved Horvitz-Thompson Estimation of Model Parameters from Two-phase Stratified Samples: Applications in Epidemiology. Statistics in biosciences 2009; 1:32.
    1. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology (Cambridge, Mass) 1999; 10:37–48.
    1. Davis NL, Miller WC, Hudgens MG, et al. Adherence to extended postpartum antiretrovirals is associated with decreased breast milk HIV-1 transmission. AIDS (London, England) 2014; 28:2739–49.
    1. Davis NL, Miller WC, Hudgens MG, et al. Maternal and Breastmilk Viral Load: Impacts of Adherence on Peripartum HIV Infections Averted—The Breastfeeding, Antiretrovirals, and Nutrition Study. JAIDS Journal of Acquired Immune Deficiency Syndromes 2016; 73:572–80.
    1. Shapiro RL, Holland DT, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. The Journal of infectious diseases 2005; 192:720–7.
    1. Mirochnick M, Thomas T, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrobial agents and chemotherapy 2009; 53:1170–6.
    1. Corbett AH, Kayira D, White NR, et al. Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post partum: results of the BAN Study. Antiviral Therapy 2014.
    1. Anderson GD. Using pharmacokinetics to predict the effects of pregnancy and maternal–infant transfer of drugs during lactation. Expert opinion on drug metabolism & toxicology 2006; 2:947–60.
    1. Riant P, Urien S, Albengres E, Duche J, Tillement J. High plasma protein binding as a parameter in the selection of betablockers for lactating women. Biochemical pharmacology 1986; 35:4579–81.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅